Research location
Zhejiang
China
Advertisement
Research activity in Zhejiang
ChinaCureCurrent currently publishes aggregate city-level research activity for this location: 45 trials and 48 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Zhejiang
45 linked trials · page 1 of 1Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLCNCT07492342 · 2026-01-29 · 1 site observation
RECRUITING
JMT106 Injection in the Treatment of Advanced Solid TumorsNCT07275073 · 2025-09-25 · 1 site observation
RECRUITING
A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid TumorsNCT07147348 · 2025-08-27 · 1 site observation
RECRUITING
Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)NCT06809764 · 2025-02-21 · 1 site observation
RECRUITING
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung CancerNCT06712355 · 2025-02-03 · 1 site observation
RECRUITING
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung CancerNCT06712316 · 2025-01-07 · 1 site observation
RECRUITING
A Study of JMT203 in Patients With Cancer CachexiaNCT06868849 · 2024-05-15 · 1 site observation
RECRUITING
A Multi-center RCT to Evaluate Subsegmental BTVA Treatment for Severe EmphysemaNCT06152107 · 2024-01-01 · 1 site observation
RECRUITING
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 MutationNCT05696626 · 2023-10-31 · 2 site observations
RECRUITING
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC PatientsNCT05899608 · 2023-10-26 · 1 site observation
RECRUITING
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination TherapyNCT05646862 · 2023-06-07 · 1 site observation
RECRUITING
Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of THDBH120 in Chinese Patients With ObesityNCT06951945 · 2024-07-18 · 1 site observation
COMPLETED
A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based ChemotherapyNCT06267001 · 2024-03-21 · 1 site observation
TERMINATED
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)NCT06065748 · 2023-12-11 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast CancerNCT05945927 · 2023-09-13 · 1 site observation
COMPLETED
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine TherapyNCT05840211 · 2023-05-08 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.NCT05763121 · 2023-01-30 · 1 site observation
TERMINATED
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTENCT05171075 · 2022-09-27 · 1 site observation
TERMINATED
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerNCT05382299 · 2022-07-20 · 2 site observations
ACTIVE_NOT_RECRUITING
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)NCT05171816 · 2021-06-24 · 2 site observations
ACTIVE_NOT_RECRUITING
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative TherapyNCT04873362 · 2021-05-04 · 1 site observation
ACTIVE_NOT_RECRUITING
Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)NCT04768296 · 2021-03-29 · 1 site observation
COMPLETED
Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese PatientsNCT04560452 · 2021-03-15 · 1 site observation
COMPLETED
Real World Study of Bone Metastases in Patients with Advanced Breast CancerNCT06873997 · 2021-01-01 · 1 site observation
COMPLETED
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)NCT04656652 · 2020-12-21 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)NCT04576455 · 2020-11-27 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)NCT04194203 · 2020-04-09 · 1 site observation
COMPLETED
A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung CancerNCT04294810 · 2020-03-04 · 1 site observation
COMPLETED
A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior TreatmentNCT04178460 · 2020-02-03 · 1 site observation
TERMINATED
Clinical Evaluation of Genetron Lung Cancer Panel in Non-small Cell Lung Cancer PatientsNCT05023746 · 2018-08-30 · 1 site observation
COMPLETED
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast CancerNCT03498716 · 2018-08-02 · 1 site observation
TERMINATED
A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)NCT03125902 · 2017-08-25 · 1 site observation
COMPLETED
Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT03088540 · 2017-05-29 · 1 site observation
COMPLETED
A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast CancerNCT02896855 · 2016-09-13 · 1 site observation
COMPLETED
A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing ChemotherapyNCT02813785 · 2016-07-01 · 1 site observation
COMPLETED
A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)NCT02763579 · 2016-06-07 · 1 site observation
COMPLETED
A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)NCT02657434 · 2016-04-30 · 1 site observation
COMPLETED
Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + DocetaxelNCT02586025 · 2016-03-14 · 1 site observation
COMPLETED
Comparison of Once Daily and Twice Daily Dosing on Safety and Tolerability of Memantine in Patients With AlzheimerNCT02553928 · 2015-10-01 · 1 site observation
COMPLETED
A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor TherapyNCT02340221 · 2015-04-09 · 1 site observation
TERMINATED
Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)NCT01982955 · 2013-12-23 · 1 site observation
COMPLETED
Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving ChemotherapyNCT02005458 · 2013-12-01 · 1 site observation
COMPLETED
Radical Resection Vs. Ablative Stereotactic Radiotherapy in Patients With Operable Stage I NSCLCNCT01753414 · 2012-12-01 · 1 site observation
UNKNOWN
A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based TreatmentNCT01702571 · 2012-11-27 · 1 site observation
COMPLETED
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast CancerNCT00528567 · 2007-12-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.